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Abstract
Objective: Primary immunodeficiencies (PID) are a heterogeneous 
group of disorders with a variable clinical spectrum of manifestations. 
The central nervous system may be involved in PID with symptoms 
which may present initially or develop at later stages. The purpose of 
this study was to review the neurological manifestations of different 
PID syndromes.
Materials & Methods: We focused on 104 selected studies on PID 
with certain neurological abnormalities which may accompany these 
disorders or may later signify a PID in their course.
Results: Diverse neurological deficits accompanying certain PIDs may 
be mild or they may greatly influence the course of the disease with 
major impacts on the quality of life of these patients.
Conclusion: Early recognition and treatment is important to prevent or 
reduce future irreversible neurological sequelae. Therefore physicians 
should be aware of the neurological features accompanying PID.
Keywords: Neurological; Primary immunodeficiencies; Neurologic 
signs and symptoms
Introduction
Primary immunodeficiencies (PID) are a heterogeneous group of 354 
distinct disorders with 344 different gene defects (1) with a variable clinical 
spectrum of manifestations. A diagnosis of PID will often be considered 
with a predisposition to frequent, severe or unusual infections, autoimmune 
disorders and malignancies or allergic disorders (2). 
PIDs have been classified practically according to the affected immune 
function to the following groups: immunodeficiencies affecting cellular 
and humoral immunity, combined immunodeficiencies with associated 
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or syndromic features, antibody deficiencies, 
diseases of immune dysregulation, congenital 
defects of phagocytes, defects in intrinsic and 
innate immunity, autoinflammatory disorders, 
complement deficiencies and phenocopies of PIDs 
(3). The central nervous system may be involved in 
PIDs with symptoms which may present initially 
or develop at later stages. The neurological 
symptoms may vary from mild cognitive defects 
to severe disabilities (4). Physical examination 
may give the clinician valuable clues to the cause 
of PIDs that underlie the neurological signs. 
Certain neurological abnormalities may later 
signify a PID. Therefore physicians should be 
aware of the neurological features accompanying 
immunodeficiencies. Neuromascular abnormality 
presenting with ataxia may be the first indicator of 
ataxia-telengiectasia. Flaccid paralysis after live 
poliovirus immunization may suggest combined 
immunodeficiency or antibody defects. Pernicious 
anaemia may later result in neurological deficits in 
untreated CVID patients. Cognitive impairment, 
nystagmus and cerebellar, spinal and peripheral 
neuropathies are neurologic features seen in 
Chediac-Higashi Syndrome. Patients with Griscelli 
syndrome may present with seizures, ataxia and 
occulomotor and reflex abnormalities. DiGeorge 
anomaly may present with subtle developmental 
delays later manifesting as problem with school 
performances (5). Early recognition and treatment 
may prevent or reduce future irreversible 
neurological sequelae (4). 
Neurological manifestations will be discussed 
in detail according to the specific classification 
of primary immunodeficiencies to assist the 
treating physicians’ timely diagnosis and prompt 
treatment in order to avoid irreversible neurologic 
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sequelae. The categorization of the inborn errors 
of immunity is based on the International Union 
of Immunological Societies: 2017 Primary 
Immunodeficiency Diseases Committee Report on 
Inborn Errors of Immunity (1).
Materials & Methods
The last version of IUIS Primary Immunodeficiencies 
Committee Report (1) on Inborn Errors of 
Immunity was reviewed first to select certain PIDs 
with neurological manifestations. Then a review 
of literature was started according to specific PID 
associated with neurological manifestations with a 
focus on 104 selected studies.
Discussion
Immunodeficiencies affecting cellular and humoral 
immunity
 Severe combined immunodeficiencies defined by 
CD3 T cell lymphopenia
Adenosine Deaminase deficiency (ADA)
ADA is a ubiquitous enzyme in purine salvage 
pathway which is also expressed in both the 
peripheral and central nervous systems (6). ADA 
deficiency is caused by mutations in the ADA gene 
and is known as one of the most prevalent forms 
of severe combined immunodeficiencies (6). The 
most common manifestations include recurrent and 
opportunistic fungal, viral and bacterial infections, 
lymphopenia and failure to thrive (7). The main 
neurologic manifestations of these diseases result 
from accumulation of adenosine metabolites in basal 
ganglia and thalamus which are rich in adenosine 
receptors. These neurologic abnormalities include 
motor delay, hypotonia, mental retardation, 
learning disability, hyperactivity, attention 
deficit, behavioural abnormalities, reduced verbal 
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expression, seizure and sensorineural deafness (4, 
8). One infant has been reported with nystagmus 
and difficulty in focusing gaze was found to have 
brain atrophy on MRI (9).
DNA Ligase IV deficiency
This autosomal recessive form of SCID is caused by 
an impairment of the DNA damage repair process 
with a pronounced radiosensitivity (10). DNA 
double-strand break repair via non-homologous 
end-joining (NHEJ) is involved in recombination 
of immunoglobulin and T-cell receptor genes. 
Mutations in NHEJ components may lead to 
microcephaly and immunodeficiency (11).The 
neurological manifestations of this disease include 
microcephaly and developmental delay (12). 
Cernunnos deficiency
This is another rare autosomal recessive form 
of SCID with severe T and B lymphopenia 
and dysgammaglobulinemia in addition to 
radiosensitivity caused by mutations in the 
CERNUNNOS or XRCC4-like factor (XLF). 
Microcephaly and developmental delay are the 
prominent neurological features (4, 8). 
CID with associated or syndromic features
Ataxia-Telengiectasia
This autosomal recessive complex disorder with 
substantial severity in affected individuals (13) 
is characterized by ataxia, ocular and cutaneous 
telengiectasia, radiosensitivity, immunodeficiency, 
increased predisposition to malignancies (14) 
and elevated serum alpha fetoprotein level. 
Sinopulmonary infections (15-17) are common 
in these patients with development of chronic 
lung disease in 25% (18). The most common 
immunologic abnormalities are low serum levels 
of one or more classes of immunoglobulin, failure 
to make antibodies in response to vaccines and 
lymphopenia (19). The ataxia telengiectasia 
mutated (ATM) gene is involved in the response to 
DNA damage in the nervous system which leads to 
impaired apoptosis and elimination of the damaged 
neurons and neurodegeneration (4). Progressive 
neurodegeneration which mainly occurs with a 
widespread loss of Purkinje cells in cerebellum is 
the hallmark of ataxia-telengiectasia, manifesting 
as head and trunk swaying and gait abnormalities 
(8, 13). It is followed by basal ganglia dysfunction 
later in the course of the disease characterised 
by hypotonia, tremor and choreoathetosis. These 
patients are usually confined to a wheelchair by 
the age of 10-12 years. In physical examination, 
further evaluation reveals diminished or absent 
tendon reflexes, positive Babinski sign, loss 
of vibration sense, abnormal ocular motility, 
reduction in sensory conduction velocity and 
axonal degeneration of peripheral nerves (8).
There are also Ataxia Telengiectasia-Like Disorders 
(ATLD) which are clinically similar to ataxia 
telengiectasia although without telangiectasia and 
a slower progression of neurologic manifestations. 
These patients remain ambulatory until their third 
decades of lives (8, 20).
Nijmegan Breakage Syndrome
This is a rare autosomal recessive, multisystemic 
disease of chromosomal instability presenting at 
birth with microcephaly but no additional neurologic 
manifestation (21). The mutated gene (NBS) has 
a critical role in responding to DNA damage. The 
defect leads to neuronal loss and microcephaly. 
“Other manifestations include combined cellular 
and humoral immunodeficiency with recurrent 
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sinopulmonary infections, a strong predisposition 
to develop malignancies and radiosensitivity” 
(21). Due to the radiation hypersensitivity in these 
patients, they are at increased risk of developing 
brain malignancies such as medulloblastoma (22). 
These patients may exhibit progressive mental 
retardation which becomes more evident after age 
of 14 years (23). as well as brain developmental 
abnormalities including partial collosal agenesis, 
hydrocephaly, colpocephaly, neuronal migration 
abnormalities. The volume of the frontal lobe 
may be reduced and the gyral pattern may become 
simplified (24). 
Immunodeficiency, Centromeric Region 
Instability and Facial Anomalies Syndrome
This genetic disease is due to a mutation in DNA 
methylteransferase gene (25) which causes DNA 
hypomethylation. It is not identified how these 
hypomethylated areas of the genome result in 
the features of this syndrome but it appears that 
the expression pattern of the genes essential 
for a functional immune system, craniofacial 
development and neurogenesis are altered in 
the deficient cells (26). ICF patients have severe 
respiratory infections and recurrent gastrointestinal 
infections due to immune abnormalities which 
include hypogammaglobulinemia despite normal 
B cell counts and a mild reduction in immune 
response. Reduced T cell counts have been detected 
in approximately half of the cases (99). Affected 
patients exhibit mental retardation, hypotonia and 
ataxia in addition to above immune abnormalities 
(25, 27).
Riddle Syndrome
This syndrome is characterized by a defect in 
DNA damage response causing immunodeficiency 
and increased radiosensitivity accompanied by 
neurologic symptoms and growth delay due to 
an increased apoptosis and reduced proliferative 
capacity during brain development presenting as 
mild motor control and learning difficulties (28). 
DiGeorge Syndrome
In addition to the characterizing triad of 
cardiac defects, hypocalcemia and cellular 
immune deficiency, there may be neurological 
manifestations which present with developmental 
delay in motor, language and speech areas, 
neuropsychiatric problems and epilepsy (4). 
Most patients show a hemizygous chromosome 
22q11.2 deletion, and most of them with 
DiGeorge syndrome show mild to moderate T 
cell lymphopenia. The most common neurologic 
manifestations include cognitive, neurologic 
and psychiatric abnormalities (8). Nearly 50% 
percent of school-age patients have problems with 
persistent language difficulties while their full-
scale IQ scores are within normal to moderately 
retarded range with math scales lower than reading 
and spelling (29, 30). Behavioural abnormalities 
include anxiety disorders, schizophrenia, ADHD, 
mood disorders and flat effect in childhood 
(31) and schizophrenia and bipolar disorders 
later during adulthood. Neural tube defects, 
polymicrogyria, volume reduction in the corpus 
callosum, amygdalae and temporoparietal regions 
(29, 32) and myelomeningocele (33) are structural 
malformations which have been described in these 
patients.
Hyper-immunoglobulin E syndrome
These syndromes are characterized by recurrent 
skin and pulmonary infections in the presence of 
elevated IgE concentration and usually eosinophilia. 
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The hyper-IgE syndromes have four distinct genetic 
causes including mutations in signal transducer 
and activator of transcription 3 (STAT3), dedicator 
of cytokinesis 8 (DOCK8), tyrosine kinase2 
(TYK2) and phosphoglucomutase 3 (PGM3) (1, 
34). Vascular abnormalities, impaired myelination 
or autoimmunity are the main suggested causes 
for neurologic manifestations in these patients 
(35, 36). Intracranial manifestations including 
Chiari I malformations and focal hyperintensities 
on brain MRI are the two findings in AD-HIED 
which are typically asymptomatic (37). Other CNS 
reported abnormalities include vasculitis resulting 
a right parietal infarction and thrombosis of the 
left posterior inferior cerebellar artery (38, 39). 
In DOCK8 deficiency neurologic manifestations 
include vasculitis, ischemic infarction, hemiplegia, 
facial paralysis, subarachnoid hemorrhages and 
progressive multifocal leukoencephalopathy (34, 
40). Patients with PGM3 mutations are reported 
to carry a high risk of early onset neurological 
impairment including developmental delay, ataxia, 
dysarthria, psychomotor retardation, hypotonia, 
sensorineural hearing loss, seizures and myoclonus 
(34, 41).
Schimke Immuno-osseous Dysplasia
This autosomal recessive disorder is caused by 
mutation in the SMARCAL1 gene which encodes 
a chromatin remodeling protein. Defective cellular 
immunity causes recurrent bacterial, fungal and viral 
infections which in association with short stature 
and progressive renal insufficiency characterizes 
the disorder (4). Neurological manifestations 
include early-onset cerebral ischemic attacks, 
Migraine-type headaches (42), optic neuropathy, 
seizures, mental retardation and behavioural 
changes (4, 43). Progressive aterosclerosis and 
intrinsic neurovascular defects are considered as 
the underlying pathologic involvement causing the 
above manifestations (44).
Hoyeraal-Hreidarsson syndrome
This is an X-linked recessive disorder of telomere 
dysfunction which represents a severe form of 
dyskeratosis congenita characterized by a classic 
triad of reticular skin pigmentation, dysplastic nails 
and oral leukoplakia (45). Pancytopenia and severe 
combined immunodeficiency (characterized by a 
decreased B cells count and Natural Killer cells 
and low immunoglobulin levels that can affect 
all immunoglobulin subtypes) may eventually 
develop (46). Dyskerin, a highly conserved 
protein is the product of DKC1 gene, involved in 
ribosome biogenesis and acts as a component of 
telomerase complex (8). Since proper telomerase 
activity is essential for early development of neural 
progenitor cells and neurons, its defective function 
may lead to increased susceptibility to DNA 
damage and apoptosis and the resultant neurologic 
deficits. These neurological abnormalities include 
microcephaly, psychomotor retardation, spasticity, 
cerebellar hypoplasia, ataxia (8), seizures and axial 
hypotonia (47).
Purine Nucleoside Phosphorylase Deficiency
This rare autosomal recessive metabolic disorder, 
similar to ADA deficiency, results from impaired 
purine salvage pathway which causes combined 
immunodeficiency in association with prominent 
neurological abnormalities (48). “Mutations 
in PNP results in impaired function of enzyme 
leading to accumulation of purine metabolites such 
as deoxy-guanosine triphosphate (dGTP) which 
preferentially is accumulated in mitochondria 
and will affect adversely mitochondrial DNA 
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repair and therefore may induce subsequent 
neuronal cell apoptosis” (8). Patients present with 
T-lymphocytopenia (49). Infectious complications 
include recurrent upper and lower respiratory tract 
infections and otitis media (48, 49). Neurological 
findings found in more than half of the patients 
often precede infections and autoimmunity (4) 
and include motor system dysfunction, cerebral 
palsy, hyper/ hypotonia, spastic paresis, tremor, 
ataxia, mental retardation, developmental delay, 
behavioural problems, cerebrovascular accidents 
and sensorineural deafness (4, 8, 48, 50). 
Hepatic Veno-Occlusive Disease with 
Immunodeficiency
This is caused by homozygous mutation in the 
autosomal SP110 gene. The onset of clinical 
features usually occurs before the age of six 
months with hepatic sinusoidal obstruction. Serum 
Ig levels are low. T cell subsets and B-cell numbers 
are reduced. Neurological abnormalities include 
leukodystrophy and extensive cerebral necrosis on 
postmortem examination are found in one third of 
the patients (51).
VICI Syndrome (Immunodeficiency with Cleft 
Lip/Palate, Cataract, Hypopigmentation and 
Absent Corpus Collasum)
This rare autosomal recessive disorder is caused 
by mutation in the EPG5 gene which results 
in defective autophagy (52). Clinical findings 
include cataracts, cleft lip and palate, progressive 
cardiomyopathy, variable pigmentary defects 
and combined immunodeficiencies. Neurologic 
manifestations include microcephaly, seizures, 
nystagmus, callosal agenesis, hypotonia and severe 
psychomotor and growth retardation (53). Some 
patients show more structural CNS abnormalities 
(52, 53). 
Predominantly Antibody deficiency
Common variable immunodeficiencies and 
agammaglobulinemia (x-linked or autosomal 
recessive) are the most frequent forms of 
presentations of antibody deficiency. Symptoms 
mainly consist of respiratory or gastrointestinal 
involvement. However, neurologic manifestations 
may also occur. 
Common Variable Immunodeficiency
Neurologic manifestations are a complex of 
diverse and rare complications of CVID including 
brain or spinal cord infections (meningitis as 
the most common neurologic manifestation), 
autoimmune involvements (featuring as axonal 
sensorimotor polyneuropathy) (54), transverse 
myelitis (55), progressive neurodegeneration (56), 
cerebral vasculitis (causing recurrent occipital 
headaches), brain granulomatous lesions (57), free 
radical mediated neuronal damage due to vitamin 
E deficiency (including sensory loss, ataxia, 
retinitis pigmentosa) (58, 59), subacute combined 
degeneration of the cord secondary to vitamin B12 
deficiency, peroneal muscular atrophy, Guillain-
Barre syndrome and myasthenia gravis (55).
Agammaglobulinemia
In patients with agammaglobulinemia 
symptoms mainly consist of recurrent 
respiratory or gastrointestinal infections. Serum 
immunoglobulins are severely decreased and 
usually undetectable (60). CNS complications may 
arise from persistent enteroviral infections which 
may lead to fatal encephalitis or dermatomyositis-
meningoencephalitis syndrome (61). “Also, a 
progressive encephalopathy of unknown etiology 
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has been described in patients with x-linked 
agammaglobulinemia with a uniform clinical 
course including cognitive and movement 
disorders” (62).
Disorders of Immune Regulation
Chediac Higashi Syndrome
Patients with this autosomal recessive lethal disorder 
present with recurrent respiratory and bacterial 
skin infections due to severe immunodeficiency, 
partial oculocutaneous albinism, bleeding tendency 
and progressive neurological features (63). This 
syndrome is caused by mutations in the lysosomal 
trafficking regulator gene (LYST) (4, 8). Neurologic 
abnormalities include weakness, areflexia, sensory 
deficits, peripheral polyneuropathy, progressive 
neurodegeneration, cognitive defects, dementia, 
ataxia, tremor, seizures, autonomic dysfunction 
and parkinsonian syndrome (64). Unfortunately 
the progression of neurological manifestations is 
not arrested by HSCT (64, 65).
Hermansky-Pudlak syndrome type 2
Among Hermansky Pudlak syndromes, this type 
is characterized by an immunodeficiency due 
to neutropenia and T lymphocyte dysfunction 
which differentiates it from other types of this 
syndrome (66). These patients usually suffer 
from recurrent bacterial infections, particularly 
respiratory illnesses, hepatosplenomegaly, lung 
fibrosis, dysmorphia, oculocutaneous albinism, 
thrombocytopenia and neurological abnormalities 
(67). Neurological manifestations include 
developmental delay, generalized seizures, 
microcephaly, hearing impairment and intention 
tremor (68, 69).
Familial Hemophagocytic Lymphohistiocytosis
FHL comprises a group of autosomal recessive 
life-threatening disorders characterized 
by uncontrolled proliferation of activated 
lymphocytes and macrophages associated with 
massive secretion of cytokines infiltrating into 
organs including lymph nodes, bone marrow, liver, 
spleen and central nervous system (70, 71). CNS 
infiltration begins in the meninges, progressing to 
diffuse infiltration of the white matter followed by 
necrosis and focal demyelination (4, 71). Therefore 
neurological manifestations vary depend on the 
areas involved including seizures, decreased 
level of consciousness, facial palsy, irritability, 
bulging fontanel, dysphagia, dysarthria, CSF 
abnormalities (leukocytosis), ataxia, nystagmus, 
visual disturbance, neck stiffness, cranial nerve 
palsies and brain death (72-74).
 Congenital defects of phagocytic number or 
function
Chronic Granulomatous Disease
Chronic granulomatous disease is the most 
common inherited disorder of phagocytic cells. It 
results from an inability of phagocytes to produce 
bactericidal superoxide anions due to defects of the 
NADPH oxidase system and it leads to the defect 
in killing of a specific spectrum of bacteria and 
fungi resulting in concomitant hyper-inflammation 
and tissue granuloma formation (75). Neurological 
manifestations are reported due to brain abscesses 
which are rare events in CGD (76). Other 
complications include white matter disease, CNS 
granulomatous disease and leptomeningeal and 
focal brain infiltration by pigmented lipid-laden 
macrophages (75).
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Severe Congenital Neutropenia
This term is used for a heterogeneous group of 
primary immunodeficiencies including sporadic 
autosomal recessive, autosomal dominant and 
x-linked types (39) of which the autosomal 
recessive type with a homozygous mutation in 
antiapoptotic protein, HAX1, accounts for one 
third of these patients and has been identified 
as the only subtype associated with neurologic 
abnormalities (40). Neurologic manifestations 
include developmental delay, cognitive defects, 
speech defects, attention deficit, hyperactivity, 
learning disabilities and epilepsy (77-79). 
Schwachman-Diamond Syndrome
This is a multisystem disorder characterized by bone 
marrow failure, exocrine pancreatic insufficiency 
and metaphyseal chondrodysplasia. These features 
are attributed to mutation in SBDS gene (80). 
However the precise pathologic pathways with the 
potential ability to disrupt the protein’s function 
remain to be identified. Neurological findings 
include neuropsychological abnormalities. These 
patients not only suffer from behavioural problems 
but also experience developmental retardation, 
low intelligence, cognitive deficits, hypotonia and 
visual motor dysfunction (81). Brain structural 
anomalies including callosal agenesis, delayed 
myelination and decreased gray and white matter 
volumes have been detected (82).
Leukocyte Adhesion Deficiency type 2
LAD syndromes consist of rare autosomal 
recessive disorders among which only LAD type 
2 presents with neurologic abnormalities. These 
patients are characterized by recurrent bacterial 
infections without pus formation in the first years 
of life and severe mental retardation later (83). 
Other neurologic manifestations include autistic 
features, microcephaly, muscular hypotonia 
and cerebral atrophy (83, 84). Strong delays in 
directional movement and severe retardation in 
speech development have been also reported (84). 
Impaired fucose metabolism has been suggested as 
the cause of neurologic manifestations (85).
β-Actin deficiency
This autosomal dominant immunodeficiency 
disorder caused by a non-lethal mutation, 
characterized by defects in neutrophil migration, 
mental retardation, short stature, thrombocytopenia 
and photosensitivity (86). The hallmark of 
the disorder is recurrent bacterial and fungal 
infections without pus formation. The neurologic 
manifestations of this defect are due to the 
contribution of β-actin in neuronal migration and 
development and particularly includes mental 
retardation. 
Autoinflammatory Disorders
Mevalonate Kinase Deficiency (MKD)
This is a term used for a wide clinical spectrum 
of autosomal recessive disorders due to a 
congenital error in cholesterol biosynthesis, with 
hyperimmunoglobulinemia D syndrome as the 
benign variant of the disorder and Mevalonic 
aciduria as the more severe form of MKD (3). 
Mevalonate kinase is an important enzyme in 
the biosynthesis of cholesterol. Recurrent, non-
infectious febrile episodes lasting 4 to 6 days, 
usually accompanied by cervical or abdominal 
lymphadenopathies, splenomegaly, vomiting, 
diarrhoea, arthralgia and erythematous/ urticarial 
rash are characteristic. Although the pathogenic 
mechanisms causing the neurological defects are 
not understood, the role of cholesterol in brain 
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development and neuronal function cannot be 
ignored. The neurological manifestations in a 
subset of patients with hyperimmunoglobulinemia 
D syndrome include mental retardation, ataxia and 
epilepsy (87). In patients with mevalonic aciduria 
due to complete MVK deficiency, neurological 
manifestations may include dysmorphic 
craniofacial features, psychomotor retardation, 
developmental delay, hypotonia and progressive 
cerebellar ataxia (88, 89). 
Neonatal Onset Multisystem Inflammatory 
Disorder
The disease results from mutations in the CIAS-
1 gene which encodes cryopyrin (90). Cryopyrin 
in association with other proteins form a protein 
complex called the inflammasome which activates 
IL-1β to its proinflammatory form. These 
mutations cause which aberrant activation of the 
inflammasome (91) are supposed to be responsible 
for the persistent upregulation of this inflammatory 
pathway (92). Therefore like other involved organs, 
the increased IL-1β activity (93) in the brain seems 
to cause the neurological symptoms which are the 
prominent manifestations of this disorder. These 
abnormalities include chronic aseptic meningitis 
which may cause increased intracranial pressure 
resulting in hydrocephalus, papilledema and optic 
nerve atrophy, spastic diplegia, hypotonia, transient 
episodes of hemiplegia, mental retardation, 
developmental delay, brain atrophy, headache, 
early morning nausea, vomiting, progressive 
sensorineural hearing loss and seizures (94). 
Blau syndrome
This rare autosomal dominant syndrome clinically 
resembles early onset sarcoidosis characterized 
by granulomatous inflammation mostly involving 
joints, eyes and skin (95-97) and is caused by 
mutation in pattern recognition receptor NOD2 
gene encoding a protein known as an intracellular 
sensor for bacterial products (98, 99). This protein 
is activated after receiving signals from bacterial 
components resulting in activation of NFkB 
pathway which regulates innate responses (99). 
Neurological manifestations are rare and include 
cranial neuropathies (hearing loss) and transient 
6th nerve palsy, cerebral vasculitis and cerebral 
infarction (100, 101).
Aicardi-Goutieres syndrome
This is a genetically determined encephalopathy 
caused by mutations in TREX1 genes encoding 
RNAs involved in removing RNA, leading to the 
accumulation of endogenous RNA, triggering Toll-
like receptor-dependent interferon-α production in 
the brain with the resultant activation of neurotoxic 
lymphocytes and immune system in addition 
to the inhibition of angiogenesis (102, 103). 
Neurological manifestations include early infantile 
onset of irritability, spasticity, dystonic posturing, 
psychomotor retardation and microcephaly, 
resulting in death in early childhood (104).
In conclusion, neurological manifestations of 
primary immunodeficiencies are common with 
diverse pathologic mechanisms. Neurological 
deficits may be mild or they may greatly influence 
the course of the disease with major impacts on 
the quality of life of the patients. Some of these 
complications may even cause death. Neurological 
manifestations may have an early onset, beginning 
at birth or they may appear later which in both 
situations may lead to misdiagnosis and delayed 
therapy. Therefore a high suspicion of an underlying 
primary immunodeficiency is important in any type 
Neurological Manifestations of Primary Immunodeficiencies
16 Iran J Child Neurol. Summer 2018 Vol. 12 No. 3
of neurological problems occurring with recurrent 
infections.
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